Biodexa Net Receivables from 2010 to 2025

BDRX Stock   3.48  0.03  0.87%   
Biodexa Pharmaceticals Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables will likely drop to about 455.7 K in 2025. During the period from 2010 to 2025, Biodexa Pharmaceticals Net Receivables regression line of annual values had r-squared of  0.01 and arithmetic mean of  489,707. View All Fundamentals
 
Net Receivables  
First Reported
2013-09-30
Previous Quarter
1.9 M
Current Value
1.9 M
Quarterly Volatility
951.5 K
 
Yuan Drop
 
Covid
Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 242 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 0.0119, Dividend Yield of 0.0 or PTB Ratio of 0.001. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
  
Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Latest Biodexa Pharmaceticals' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Biodexa Pharmaceticals over the last few years. It is Biodexa Pharmaceticals' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodexa Pharmaceticals' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Very volatile
   Net Receivables   
       Timeline  

Biodexa Net Receivables Regression Statistics

Arithmetic Mean489,707
Geometric Mean244,172
Coefficient Of Variation123.92
Mean Deviation441,758
Median189,000
Standard Deviation606,841
Sample Variance368.3B
Range2.2M
R-Value0.07
Mean Square Error392.5B
R-Squared0.01
Significance0.79
Slope9,109
Total Sum of Squares5.5T

Biodexa Net Receivables History

2025455.7 K
2024633.6 K
2023704 K
2022329 K
202133 K
202095 K
201922 K

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables633.6 K455.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.